179 related articles for article (PubMed ID: 34790279)
1. Systematic Analysis Uncovers Associations of PGK1 with Prognosis and Immunological Characteristics in Breast Cancer.
Li L; Bai Y; Gao Y; Li D; Chen L; Zhou C; Feng M; Chen X; Jin W; Cao Y
Dis Markers; 2021; 2021():7711151. PubMed ID: 34790279
[TBL] [Abstract][Full Text] [Related]
2. PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1α-Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer.
Fu D; He C; Wei J; Zhang Z; Luo Y; Tan H; Ren C
Cell Physiol Biochem; 2018; 51(5):2434-2444. PubMed ID: 30537744
[TBL] [Abstract][Full Text] [Related]
3. Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis.
Shao F; Yang X; Wang W; Wang J; Guo W; Feng X; Shi S; Xue Q; Gao S; Gao Y; Lu Z; He J
Cancer Commun (Lond); 2019 Oct; 39(1):54. PubMed ID: 31578148
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
Ji H; Ren M; Liu T; Sun Y
Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
[TBL] [Abstract][Full Text] [Related]
5. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
6. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
7. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
Sun S; Liang X; Zhang X; Liu T; Shi Q; Song Y; Jiang Y; Wu H; Jiang Y; Lu X; Pang D
Br J Cancer; 2015 Apr; 112(8):1332-9. PubMed ID: 25867275
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value and immunological role of PDCD1 gene in pan-cancer.
Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D
Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926
[TBL] [Abstract][Full Text] [Related]
9. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
10. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
11. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.
Chu Z; Huo N; Zhu X; Liu H; Cong R; Ma L; Kang X; Xue C; Li J; Li Q; You H; Zhang Q; Xu X
Mol Ther; 2021 Sep; 29(9):2737-2753. PubMed ID: 33940159
[TBL] [Abstract][Full Text] [Related]
12. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
13. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
Wen J; Mao X; Cheng Q; Liu Z; Liu F
Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics.
Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J
Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104
[TBL] [Abstract][Full Text] [Related]
15. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
17. Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.
Ye H; Zhang N
Comput Math Methods Med; 2021; 2021():1498924. PubMed ID: 34868337
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer.
Jiang F; Wu C; Wang M; Wei K; Wang J
Sci Rep; 2021 Feb; 11(1):3986. PubMed ID: 33597614
[TBL] [Abstract][Full Text] [Related]
19. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
